American Well Corporation (AMWL)
USD 7.33
(0.41%)
USD 7.33
(0.41%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -225.99 Million USD | 12.16% |
| 2022 | -249.68 Million USD | -53.13% |
| 2021 | -162.2 Million USD | 24.95% |
| 2020 | -216.92 Million USD | -149.91% |
| 2019 | -85.44 Million USD | -74.67% |
| 2018 | -48.59 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -39.13 Million USD | 33.89% |
| 2024 Q3 | -31.12 Million USD | 11.56% |
| 2024 Q1 | -58.05 Million USD | -32.27% |
| 2023 Q3 | 22.69 Million USD | 170.4% |
| 2023 FY | - USD | 12.16% |
| 2023 Q1 | 270.53 Million USD | 564.69% |
| 2023 Q2 | -32.23 Million USD | -111.92% |
| 2023 Q4 | -47.5 Million USD | -309.34% |
| 2022 Q2 | -62.68 Million USD | 1.88% |
| 2022 Q1 | -63.88 Million USD | -57.1% |
| 2022 Q3 | -64.72 Million USD | -3.27% |
| 2022 Q4 | -58.21 Million USD | 10.05% |
| 2022 FY | - USD | -53.13% |
| 2021 Q2 | -35.05 Million USD | 3.26% |
| 2021 Q4 | -40.66 Million USD | 20.44% |
| 2021 Q3 | -51.11 Million USD | -45.82% |
| 2021 FY | - USD | 24.95% |
| 2021 Q1 | -36.23 Million USD | 22.55% |
| 2020 FY | - USD | -149.91% |
| 2020 Q4 | -46.77 Million USD | 24.2% |
| 2020 Q3 | -61.71 Million USD | 27.67% |
| 2020 Q2 | -85.32 Million USD | -263.62% |
| 2020 Q1 | -23.46 Million USD | -4.76% |
| 2019 FY | - USD | -74.67% |
| 2019 Q4 | -22.39 Million USD | 6.21% |
| 2019 Q3 | -23.88 Million USD | -22.73% |
| 2019 Q2 | -19.45 Million USD | 8.24% |
| 2019 Q1 | -21.2 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Doximity, Inc. | 195.46 Million USD | 215.616% |
| Evolent Health, Inc. | -24.78 Million USD | -811.806% |
| MultiPlan Corporation | 651.93 Million USD | 134.665% |
| Phreesia, Inc. | -102.94 Million USD | -119.526% |
| Teladoc Health, Inc. | 153.99 Million USD | 246.75% |
| Veeva Systems Inc. | 429.33 Million USD | 152.638% |